Original Research
Published on 24 Oct 2024
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis
in Multiple Sclerosis and Neuroimmunology
- 1,937 views
Original Research
Published on 24 Oct 2024
in Multiple Sclerosis and Neuroimmunology
Review
Published on 22 Oct 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 10 Oct 2024
in Multiple Sclerosis and Neuroimmunology
Systematic Review
Published on 02 Oct 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 19 Sep 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 12 Sep 2024
in Multiple Sclerosis and Neuroimmunology
Systematic Review
Published on 12 Sep 2024
in Multiple Sclerosis and Neuroimmunology
Editorial
Published on 03 Sep 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 29 Aug 2024
in Multiple Sclerosis and Neuroimmunology
Editorial
Published on 28 Aug 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 23 Aug 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 19 Aug 2024
in Multiple Sclerosis and Neuroimmunology
Study Protocol
Published on 13 Aug 2024
in Multiple Sclerosis and Neuroimmunology
Original Research
Published on 08 Aug 2024
in Multiple Sclerosis and Neuroimmunology
Review
Published on 01 Aug 2024
in Multiple Sclerosis and Neuroimmunology
Editorial
Published on 26 Jul 2024
in Multiple Sclerosis and Neuroimmunology